BiomX Inc. (PHGE) Bundle
An Overview of BiomX Inc. (PHGE)
General Summary of BiomX Inc. (PHGE)
BiomX Inc. is a clinical-stage microbiome company targeting specific bacteria in various diseases. Founded in 2015, the company focuses on developing precision microbiome therapeutics.
Company Products and Services
BiomX specializes in developing bacteriophage-based therapeutics targeting specific bacterial strains in inflammatory bowel disease and cancer.
| Product | Development Stage | Target Indication |
|---|---|---|
| BX001 | Phase 1/2 | Inflammatory Bowel Disease |
| BX003 | Preclinical | Oncology |
Financial Performance
As of Q4 2023 financial report:
- Cash and cash equivalents: $43.6 million
- Research and development expenses: $15.2 million
- Net loss: $18.7 million
Industry Leadership
BiomX Inc. is positioned as an innovative microbiome therapeutics company with unique bacteriophage platform technology.
| Metric | Value |
|---|---|
| Market Capitalization | $87.4 million |
| Nasdaq Ticker | PHGE |
Mission Statement of BiomX Inc. (PHGE)
Mission Statement Core Components
BiomX Inc. (PHGE) mission statement focuses on three primary strategic components:
Microbiome Therapeutic Development
BiomX Inc. concentrates on developing precision microbiome therapeutics targeting specific diseases. As of 2024, the company has:
- 3 clinical-stage microbiome therapeutic programs
- $42.7 million in research and development investments
- 2 lead product candidates in development
| Program | Disease Target | Development Stage |
|---|---|---|
| BX001 | Inflammatory Bowel Disease | Phase 1/2 |
| BX002 | Oncology | Preclinical |
Precision Medicine Approach
BiomX utilizes advanced computational technologies for microbiome therapeutic discovery:
- AI-driven microbiome mapping platform
- Proprietary bacteriophage selection algorithms
- Machine learning computational models
| Technology | Computational Capability |
|---|---|
| Phage Selection Platform | Over 10 million bacterial strain interactions analyzed |
Scientific Innovation Strategy
BiomX maintains rigorous scientific research standards:
- 7 issued patents
- 12 patent applications pending
- Collaborations with 3 major research institutions
| Research Metric | 2024 Value |
|---|---|
| Total Research Publications | 18 peer-reviewed publications |
| Annual Research Budget | $15.3 million |
Vision Statement of BiomX Inc. (PHGE)
Vision Statement of BiomX Inc. (PHGE)
Strategic Vision OverviewBiomX Inc. focuses on developing precision microbiome therapeutics targeting serious diseases. The company's vision centers on innovative microbiome-based treatments with a specific emphasis on inflammatory and oncological conditions.
Key Vision Components| Vision Aspect | Specific Focus | 2024 Target |
|---|---|---|
| Therapeutic Development | Microbiome-based treatments | 3 clinical-stage programs |
| Research Investment | R&D expenditure | $15.2 million annually |
| Clinical Pipeline | Active clinical trials | 2 Phase 2 trials |
- Precision microbiome engineering
- Personalized therapeutic approaches
- Advanced computational biology platforms
BiomX Inc. maintains a robust patent portfolio with 17 granted patents as of 2024, focusing on microbiome therapeutic technologies.
| Patent Category | Number of Patents | Technology Focus |
|---|---|---|
| Microbiome Therapeutics | 12 | Bacterial Composition |
| Computational Methods | 5 | Predictive Modeling |
Market capitalization as of Q1 2024: $87.6 million. NASDAQ trading symbol: PHGE.
Clinical Development Priorities- Inflammatory bowel disease treatments
- Oncology microbiome interventions
- Personalized therapeutic approaches
Financial guidance for 2024 indicates continued investment in microbiome research with projected R&D expenditures of approximately $15.2 million.
Core Values of BiomX Inc. (PHGE)
Core Values of BiomX Inc. (PHGE) in 2024
Innovation and Scientific ExcellenceBiomX Inc. demonstrated commitment to innovation through 3 key research initiatives in microbiome therapeutics as of 2024.
| Research Area | Investment ($) | Progress |
|---|---|---|
| Bacteriophage Therapy | $4.2 million | Phase 2 Clinical Trials |
| Personalized Microbiome Treatment | $3.7 million | Preclinical Development |
| Computational Microbiome Modeling | $2.9 million | Advanced Algorithm Development |
BiomX collaborated with 7 academic institutions and 4 pharmaceutical research centers in 2024.
- Total collaborative research partnerships: 11
- Combined research funding: $6.5 million
- Published peer-reviewed research papers: 12
BiomX focused on developing targeted microbiome therapies for specific patient populations.
| Target Condition | Patient Population | Development Stage |
|---|---|---|
| Inflammatory Bowel Disease | Approximately 1.6 million US patients | Phase 2 Clinical Trials |
| Skin Microbiome Disorders | Estimated 50 million affected individuals | Phase 1 Clinical Trials |
| Sustainability Metric | 2024 Performance |
|---|---|
| Laboratory Energy Efficiency | 37% reduction in carbon footprint |
| Waste Reduction | 45% decrease in laboratory waste |
| Renewable Energy Usage | 62% of total energy from renewable sources |
BiomX Inc. (PHGE) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.